Abstract
This is a review of the epidemiology and management of infectious complications in contemporary management of chronic leukemias. Patients with chronic leukemias typically are affected by nuisance infections due to the underlying hematologic condition, particularly hypogammaglobulinemia in CLL patients. With active treatment, particularly those agents that cause defects in cell-mediated immunity, the incidence of opportunistic infections increases although endogenous bacterial, mycobacterial, and fungal infections also occur. Exogenous treatment with immunoglobulin and antimicrobial prophylaxis, particularly anti-Pneumocystis prophylaxis, may be indicated in select patients. Routine vaccinations should be maintained in these patients and vaccination early in the course of treatment may result in improve protection.
Keywords: Chronic myelogenous leukemia (CML), chronic granulocytic leukemia (CGL), chronic lymphoid leukemia (CLL), hypogammaglobulinemia, opportunistic infection, Pneumocystis, anti-Pneumocystis prophylaxis, B-cell chronic, white blood cells, alkylating, prednisone, rituximab, alemtuzumab, hairy cell leukemia, neutropenia, monocytopenia, T-cell dysfunction, Sweet's syndrome, chronic myelogenous, myeloid, stem cells, chronic granulocytic leukemia, Allogeneic hematopoietic stem cell, mycobacteria, Aspergillus, legionellosis, salmonellosis, toxoplasmosis, listeriosis, Listeria, Pas-teurella multocida tracheobronchitis, Toxoplasma cyst, Cryptococcus, Chlamydophila psittaci
Infectious Disorders - Drug Targets
Title: Epidemiology and Management of Infectious Complications in Contemporary Management of Chronic Leukemias
Volume: 11 Issue: 1
Author(s): Jo-Anne H. Young
Affiliation:
Keywords: Chronic myelogenous leukemia (CML), chronic granulocytic leukemia (CGL), chronic lymphoid leukemia (CLL), hypogammaglobulinemia, opportunistic infection, Pneumocystis, anti-Pneumocystis prophylaxis, B-cell chronic, white blood cells, alkylating, prednisone, rituximab, alemtuzumab, hairy cell leukemia, neutropenia, monocytopenia, T-cell dysfunction, Sweet's syndrome, chronic myelogenous, myeloid, stem cells, chronic granulocytic leukemia, Allogeneic hematopoietic stem cell, mycobacteria, Aspergillus, legionellosis, salmonellosis, toxoplasmosis, listeriosis, Listeria, Pas-teurella multocida tracheobronchitis, Toxoplasma cyst, Cryptococcus, Chlamydophila psittaci
Abstract: This is a review of the epidemiology and management of infectious complications in contemporary management of chronic leukemias. Patients with chronic leukemias typically are affected by nuisance infections due to the underlying hematologic condition, particularly hypogammaglobulinemia in CLL patients. With active treatment, particularly those agents that cause defects in cell-mediated immunity, the incidence of opportunistic infections increases although endogenous bacterial, mycobacterial, and fungal infections also occur. Exogenous treatment with immunoglobulin and antimicrobial prophylaxis, particularly anti-Pneumocystis prophylaxis, may be indicated in select patients. Routine vaccinations should be maintained in these patients and vaccination early in the course of treatment may result in improve protection.
Export Options
About this article
Cite this article as:
H. Young Jo-Anne, Epidemiology and Management of Infectious Complications in Contemporary Management of Chronic Leukemias, Infectious Disorders - Drug Targets 2011; 11 (1) . https://dx.doi.org/10.2174/187152611794407755
DOI https://dx.doi.org/10.2174/187152611794407755 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Usefulness of Clopidogrel Pharmacogenetics in Ce rebral Endovascular Procedures and Carotid Artery Stenting
Current Clinical Pharmacology Type 1 Diabetes Mellitus - Risk Factor for Cardiovascular Disease Morbidity and Mortality
Current Diabetes Reviews Microdialysis in Neurointensive Care
Current Pharmaceutical Design Advances of Mesenchymal Stem Cells Derived from Bone Marrow and Dental Tissue in Craniofacial Tissue Engineering
Current Stem Cell Research & Therapy Chemistry and Theranostic Applications of Radiolabeled Nanoparticles for Cardiovascular, Oncological, and Pulmonary Research
Current Topics in Medicinal Chemistry Safety of Drug Eluting Stents: Current Concerns and Controversies
Current Drug Safety A Survey on Medical Image Segmentation
Current Medical Imaging Editorial
Current Medical Imaging ESVS Guidelines: Section A - Prevention in Patients with Carotid Stenosis
Current Vascular Pharmacology Peripheral Arterial Disease: The Magnitude of the Problem and its Socioeconomic Impact
Current Drug Targets - Cardiovascular & Hematological Disorders Inflammatory Biomarkers and Cardiovascular Risk Assessment. Current Knowledge and Future Perspectives
Current Pharmaceutical Design 30 Years Lost in Anesthesia Theory
Cardiovascular & Hematological Agents in Medicinal Chemistry Progression of Alzheimer-type Neurofibrillary Tangles is Related to the Proximodistal Segments of the Hemispheric Arteries
Current Alzheimer Research Adverse Bioeffects of Ultrasound Contrast Agents Used in Echocardiography: True Safety Issue or “Much Ado About Nothing”?
Current Vascular Pharmacology Molecular Evidence of Cryptotanshinone for Treatment and Prevention of Human Cancer
Anti-Cancer Agents in Medicinal Chemistry Editorial: microRNAs: Potential Targets for the Treatment of Cardiovascular Disease
Current Vascular Pharmacology Extracellular Matrix in Atherosclerosis: Hyaluronan and Proteoglycans Insights
Current Medicinal Chemistry Pharmacotherapy Before and After Endovascular Repair of Abdominal Aortic Aneurysms
Current Vascular Pharmacology Development and Evaluation of poly(3-hydroxybutyrate-co-3-hydroxyvalerate) and Polycaprolactone Microparticles of Nimodipine
Current Pharmaceutical Design Trefoil Factor Family (TFF) Peptides and their Different Roles in the Mucosal Innate Immune Defense and More: An Update
Current Medicinal Chemistry